tadalafil has been researched along with Cancer of Liver in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 3 (75.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gong, W; Jiang, Y; Kong, D; Liu, H; Miao, X; Wu, Z | 1 |
| Chhonker, SK; Koiri, RK; Rawat, D | 1 |
| Cai, M; Deng, S; Guo, Y; Hong, X; Huang, J; Huang, W; Lin, L; Liu, J; Wang, X; Wang, Y; Xiao, Z; Zhang, Q; Zhou, J; Zhu, K | 1 |
| Agdashian, D; Brown, ZJ; Fu, Q; Greten, TF; Heinrich, B; Korangy, F; Ma, C; Rosato, U; Sandhu, M; Yu, SJ; Zhang, Q | 1 |
4 other study(ies) available for tadalafil and Cancer of Liver
| Article | Year |
|---|---|
Tadalafil enhances the therapeutic efficacy of BET inhibitors in hepatocellular carcinoma through activating Hippo pathway.
Topics: Animals; Azepines; Carcinoma, Hepatocellular; Cyclic Nucleotide Phosphodiesterases, Type 5; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Hippo Signaling Pathway; Humans; Liver Neoplasms; Mice; Nerve Tissue Proteins; Phosphodiesterase 5 Inhibitors; Proto-Oncogene Proteins c-myc; Receptors, Cell Surface; Tadalafil; Triazoles; YAP-Signaling Proteins | 2021 |
Repurposing PDE5 inhibitor tadalafil and sildenafil as anticancer agent against hepatocellular carcinoma via targeting key events of glucose metabolism and multidrug resistance.
Topics: Aflatoxin B1; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Carbolines; Carcinoma, Hepatocellular; Cyclic Nucleotide Phosphodiesterases, Type 5; Drug Repositioning; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Glucose; Imidazoles; Liver Neoplasms; Neoplasm Proteins; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Rats; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2022 |
T cell-mediated targeted delivery of tadalafil regulates immunosuppression and polyamine metabolism to overcome immune checkpoint blockade resistance in hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Humans; Immune Checkpoint Inhibitors; Immunosuppression Therapy; Liver Neoplasms; Polyamines; T-Lymphocytes; Tadalafil; Tumor Microenvironment | 2023 |
Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.
Topics: Adoptive Transfer; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Combined Modality Therapy; Cytokine-Induced Killer Cells; Cytokines; Female; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Myeloid-Derived Suppressor Cells; Phosphodiesterase 5 Inhibitors; Signal Transduction; Tadalafil; Tumor Burden; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2019 |